Skip to content
Screener

Total Liabilities at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.5B+30.1%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$182.93M+10.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.64B+44.4%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$14.95M+42.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$421.64M+19.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$106.33M+430%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemMarch 31,2026December 31,2025
Operating lease liabilities, non-current41,31942,052
Deferred revenue, non-current3,3463,810
Other liabilities4,9263,240
TOTAL LIABILITIES120,677134,174
Commitments and contingencies (Note 6)
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2026 or December 31, 2025
Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 105,314 shares issued and outstanding at March 31, 2026; 95,575 shares issued and outstanding at December 31, 20252,828,2042,407,757

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's total liabilities?
Crinetics Pharmaceuticals (CRNX) reported total liabilities of $120.68M in Q1 2026.
How has Crinetics Pharmaceuticals's total liabilities changed year-over-year?
Crinetics Pharmaceuticals's total liabilities increased by 12.4% year-over-year, from $107.33M to $120.68M.
What is the long-term trend for Crinetics Pharmaceuticals's total liabilities?
Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's total liabilities has grown at a 56.0% compound annual growth rate (CAGR), from $14.53M to $134.17M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Crinetics Pharmaceuticals's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude